Effect of denosumab on bone turnover markers in postmenopausal osteoporosis: Initial response and subsequent release from suppression

被引：0
|
作者：
Eastell, R. [1 ]
Austin, M. [2 ]
Martin, J. San [3 ]
McClung, M. R. [4 ]
Christiansen, C. [5 ]
Libanati, C. [3 ]
Siris, E. S. [6 ]
Cummings, S. R. [7 ]
机构：
[1] Univ Sheffield, Acad Unit Bone Metab, Sheffield, S Yorkshire, England
[2] Amgen Inc, Clin Biostat, Thousand Oaks, CA 91320 USA
[3] Amgen Inc, Dept Med, Thousand Oaks, CA 91320 USA
[4] Univ Oregon, Oregon Osteoporosis Ctr, Portland, OR USA
[5] Ctr Clin & Basic Res, Dept Med, Ballerup, Denmark
[6] Columbia Univ, Med Ctr, Dept Med, New York, NY USA
[7] UCSF, Clin Trial Coordinating Ctr, San Francisco, CA USA
来源：
BONE | 2009年 / 44卷 / 02期
关键词：
D O I：
10.1016/j.bone.2009.03.105
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S242 / S243
页数：2
相关论文
共 50 条
  • [21] Prognostic interest of bone turnover markers in the management of postmenopausal osteoporosis
    Chopin, Florence
    Biver, Emmanuel
    Funck-Brentano, Thomas
    Bouvard, Beatrice
    Coiffier, Guillaume
    Garnero, Patrick
    Thomas, Thierry
    JOINT BONE SPINE, 2012, 79 (01) : 26 - 31
  • [22] Endotoxin and bone turnover markers in postmenopausal women with and without osteoporosis
    Aziz, Ibrahim
    Yakout, Sobhy M.
    Aljohani, Naji
    Al-Saleh, Yousef
    Al-Attas, Omar S.
    Alokail, Majed S.
    Amer, Osama E.
    Sheshah, Eman
    McTernan, Philip G.
    Al-Daghri, Nasser M.
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (10): : 10682 - 10687
  • [23] ENDOTOXIN AND BONE TURNOVER MARKERS IN POSTMENOPAUSAL SAUDIS WITH AND WITHOUT OSTEOPOROSIS
    Al-Daghri, N.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S441 - S442
  • [24] The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis
    Szulc, Pawel
    CLINICAL BIOCHEMISTRY, 2012, 45 (12) : 907 - 919
  • [25] Bone Turnover and the Response to Alendronate Treatment in Postmenopausal Osteoporosis
    S. Gonnelli
    C. Cepollaro
    C. Pondrelli
    S. Martini
    A. Montagnani
    R. Monaco
    C. Gennari
    Calcified Tissue International, 1999, 65 : 359 - 364
  • [26] Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis
    Gonnelli, S
    Cepollaro, C
    Pondrelli, C
    Martini, S
    Montagnani, A
    Monaco, R
    Gennari, C
    CALCIFIED TISSUE INTERNATIONAL, 1999, 65 (05) : 359 - 364
  • [27] EFFECT OF VITAMIN D THERAPY ON BONE TURNOVER MARKERS IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AND OSTEOPENIA
    Tanzy, Margaret E.
    Camacho, Pauline M.
    ENDOCRINE PRACTICE, 2011, 17 (06) : 873 - 879
  • [28] Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis
    M. R. McClung
    K. Lippuner
    M. L. Brandi
    J. R. Zanchetta
    H. G. Bone
    R. Chapurlat
    D. Hans
    A. Wang
    C. Zapalowski
    C. Libanati
    Osteoporosis International, 2017, 28 : 2967 - 2973
  • [29] Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis
    McClung, M. R.
    Lippuner, K.
    Brandi, M. L.
    Zanchetta, J. R.
    Bone, H. G.
    Chapurlat, R.
    Hans, D.
    Wang, A.
    Zapalowski, C.
    Libanati, C.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 (10) : 2967 - 2973
  • [30] RELATIONSHIP BETWEEN REDUCTION IN BONE TURNOVER MARKERS (BTM) AND CHANGE IN BONE MINERAL DENSITY (BMD) IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS TREATED WITH DENOSUMAB
    Eastell, R.
    Christiansen, C.
    Grauer, A.
    Kutilek, S.
    Libanati, C.
    McClung, M.
    Resch, H.
    Siris, E.
    Uebelhart, D.
    Reid, I.
    Wang, A.
    Weryha, G.
    Cummings, S.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 185 - 186
12345